tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Fredericks S et al. | Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. | 2006 | Transplantation | pmid:16969296 |
| Peterson LB et al. | A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. | 1998 | Transplantation | pmid:9448137 |
| Alloway RR | Mounting Clinical Evidence With Tacrolimus Generic Products. | 2017 | Transplantation | pmid:28749820 |
| Rolles K et al. | A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. | 1999 | Transplantation | pmid:10551650 |
| Lee D et al. | Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. | 2017 | Transplantation | pmid:27779572 |
| Bayer ND et al. | Association of metabolic syndrome with development of new-onset diabetes after transplantation. | 2010 | Transplantation | pmid:20724958 |
| Mañez R et al. | Fluconazole therapy in transplant recipients receiving FK506. | 1994 | Transplantation | pmid:7515201 |
| Hirose R et al. | Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. | 2000 | Transplantation | pmid:10670644 |
| Sakr M et al. | Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients. | 1992 | Transplantation | pmid:1373535 |
| Hirano Y et al. | Morphological and functional changes of islets of Langerhans in FK506-treated rats. | 1992 | Transplantation | pmid:1373536 |
| Hoffman AL et al. | The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. | 1990 | Transplantation | pmid:1690469 |
| Naesens M et al. | The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. | 2007 | Transplantation | pmid:17700162 |
| Kato T et al. | Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. | 2007 | Transplantation | pmid:17984834 |
| Sindhi R et al. | Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. | 2001 | Transplantation | pmid:11571449 |
| Koenen HJ et al. | Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. | 2003 | Transplantation | pmid:12792519 |
| Hricik DE et al. | Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. | 2007 | Transplantation | pmid:17297401 |
| First MR | Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population. | 2001 | Transplantation | pmid:11585240 |
| Koomans HA and Ligtenberg G | Mechanisms and consequences of arterial hypertension after renal transplantation. | 2001 | Transplantation | pmid:11585243 |
| Tarumi K et al. | CTLA4IgG treatment induces long-term acceptance of rat small bowel allografts. | 1999 | Transplantation | pmid:10071020 |
| Trimarchi HM et al. | FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. | 1999 | Transplantation | pmid:10071024 |
| Sokal EM et al. | Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. | 1997 | Transplantation | pmid:9392308 |
| Abu-Qaoud MS et al. | Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. | 2012 | Transplantation | pmid:23044666 |
| Woodward RS et al. | Renal graft survival and calcineurin inhibitor. | 2005 | Transplantation | pmid:16177637 |
| Heilman RL et al. | Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. | 2011 | Transplantation | pmid:21775930 |
| Yamazaki S et al. | Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. | 2008 | Transplantation | pmid:18852671 |
| Kiuchi T | CNIs: immediate benefits but storing problems for the future? | 2008 | Transplantation | pmid:18946338 |
| Textor SC et al. | Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. | 1993 | Transplantation | pmid:7685934 |
| Kandula P et al. | Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. | 2012 | Transplantation | pmid:23037007 |
| Roth D et al. | Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. | 1998 | Transplantation | pmid:9458023 |
| Irish W et al. | Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. | 2003 | Transplantation | pmid:14688516 |
| Furlan V et al. | Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. | 1995 | Transplantation | pmid:7537398 |
| Chisholm MA et al. | Coadministration of tacrolimus with anti-acid drugs. | 2003 | Transplantation | pmid:12973105 |
| Shapiro R et al. | A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. | 1999 | Transplantation | pmid:10030287 |
| Paty BW et al. | Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. | 2002 | Transplantation | pmid:11884930 |
| Dell'Antonio G and Randhawa PS | "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. | 1999 | Transplantation | pmid:10030300 |
| Kelly PA et al. | Ciprofloxacin does not block the antiproliferative effect of tacrolimus. | 1997 | Transplantation | pmid:9000686 |
| Ueda M et al. | A proposal of FK506 optimal dosing in living related liver transplantations. | 1995 | Transplantation | pmid:7544035 |
| Vafadari R et al. | Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. | 2012 | Transplantation | pmid:22960764 |
| MacDonald A | Improving tolerability of immunosuppressive regimens. | 2001 | Transplantation | pmid:11833142 |
| Mollevà DG et al. | Heart and liver xenotransplantation under low-dose tacrolimus: graft survival after withdrawal of immunosuppression. | 2001 | Transplantation | pmid:11213062 |
| Raggi MC et al. | Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. | 2010 | Transplantation | pmid:21076373 |
| Sahara H et al. | Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. | 2010 | Transplantation | pmid:21076382 |
| Ciancio G et al. | A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. | 2013 | Transplantation | pmid:23903014 |
| Mathew A et al. | Reversal of steroid-resistant rejection in renal allograft recipients using FK506. | 1995 | Transplantation | pmid:7482730 |
| Lerut J et al. | Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. | 2005 | Transplantation | pmid:16314784 |
| Komori K et al. | The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. | 2008 | Transplantation | pmid:18192920 |
| Fuchinoue S et al. | Kidney transplantation after liver transplantation from the same donor: four cases of successful steroid withdrawal. | 2002 | Transplantation | pmid:11923698 |
| Lauzurica R et al. | Tacrolimus-associated severe bilateral corneal ulcer after renal transplantation. | 2002 | Transplantation | pmid:11923710 |
| Gruber SA and Doshi MD | Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. | 2010 | Transplantation | pmid:20440195 |
| Mayer AD et al. | Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. | 1997 | Transplantation | pmid:9275110 |